Impact News +++ Aktuell zu Ihren Aktien: YOC (Boersengefluester) +++ YOC Aktie -3,36%

INVION Aktie

>INVION Performance

1 Woche: 0%

1 Monat: +84,1%

3 Monate: +5,5%

6 Monate: -66,3%

1 Jahr: +3,0%

laufendes Jahr: -66,7%

>INVION Aktie

Name:

INVION LTD

Land:

Australien

Sektor:

Gesundheit

ISIN/ Wkn:

AU000000IVX4 / A1J3RR

Symbol/ Ticker:

7C8 (Frankfurt)

Kürzel:

FRA:7C8, ETR:7C8, 7C8:GR

Index:

Webseite:

Marktkapitalisierung:

6.44 Mio. EUR

Umsatz:

1.27 Mio. EUR

EBITDA:

-5.17 Mio. EUR

Gewinn je Aktie:

-0.052 EUR

Schulden:

Liquide Mittel:

0.64 Mio. EUR

Umsatz-/ Gewinnwachstum:

-99.9% / -

KGV/ KGV lG:

- / -

KUV/ KBV/ PEG:

3.53 / 0.67 / -

Gewinnm./ Eigenkapitalr.:

- / -43.8%

Dividende je Aktie:

Dividendenrendite/ -schätzung:

- / -

Insiderhandel:

Suchwörter:

INVION

Letzte Datenerhebung:

25.06.25

>INVION Eigentümer

Aktien: 84.73 Mio. St.

f.h. Aktien: 48.19 Mio. St.

Insider Eigner: 37.47%

Instit. Eigner: 2.13%

Leerverk. Aktien: -

>INVION Peer Group

ACRUX

BPH GLOBAL

CANN GROUP

MEMPHASYS

MONASH IVF

PARAGON CARE

SOMNOMED

STARPHARMA

STRUCTURAL MONITORING

SYNTARA

>INVION Chart & Kurs - Frankfurt
- Boerse Frankfurt
- >Profi Charts

>INVION News

29.05.25 - 05:48

Invion advances skin cancer treatment with positive safety data for INV043 in Phase I/II trial (Small Caps)

Invion (ASX: IVX) has reported no adverse events from the application and use of its lead drug candidate INV043 on the first six patients of a Phase I/II non-melanoma skin cancer (NMSC) trial in Queensland. Data from a safety review committee (SRC) suggested that treatment with the novel photosensitiser was well-tolerated and feedback from clinicians […] The post Invion advances skin cancer treatment with positive safety data for INV043 in Phase I/II trial appeared first on Small Caps....

04.03.25 - 08:09	XFRA : 7C8: Wiederaufnahme/Resumption (XETRA)
	FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE. THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE: INSTRUMENT NAME KUERZEL/SHORTCODE ISIN INVION LTD 7C8 AU000000IVX4 AB/FROM ONWARDS 04.03.2025...

04.03.25 - 04:48	Invion raises $2M in share placement to support cancer research work (Market Herald)
	Biotech company Invion Ltd (ASX:IVX) is raising $2 million in a two-tranche…...

28.02.25 - 07:54	XFRA : 7C8: Aussetzung/Suspension (XETRA)
	DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT: THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT: INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTIL INVION LTD 7C8 AU000000IVX4 BAW/UFN...

28.02.25 - 07:48	XFRA : INSTRUMENT_SUSPENSION - AU000000IVX4 (XETRA)
	Instrument ID [1504] (7C8 - AU000000IVX4) suspended...

03.12.24 - 02:03	Australia′s Invion jumps most in 3 yrs as skin cancer treatment trial begins (Reuters EN)
	BUZZ-Australia's Invion jumps most in 3 yrs as skin cancer treatment trial begins Shares of Invion IVX.AX rise as much as 130.6% to A$0.415, posting their biggest intraday percentage gain since Oct. 28, 2021 Stock hits its highest level since July 16 ** Cancer treatment developer says the first patient has been dosed in the early-stage trial...

03.12.24 - 02:01

Invion commences dosing in INV043 trial to treat non-melanoma skin cancer (Small Caps)

Clinical-stage life sciences company Invion (ASX: IVX) has dosed the first patient in its Phase I/II non-melanoma skin cancer (NMSC) trial using active pharmaceutical ingredient and lead candidate INV043. The trial will aim to evaluate the safety and efficacy of the topically applied INV043, a novel photosensitiser developed in Australia for use in photodynamic therapy […] The post Invion commences dosing in INV043 trial to treat non-melanoma skin cancer appeared first on Small Caps....

29.11.24 - 09:27	XFRA : 7C8: Wiederaufnahme/Resumption (XETRA)
	FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE. THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE: INSTRUMENT NAME KUERZEL/SHORTCODE ISIN INVION LTD 7C8 AU000000IVX4 AB/FROM ONWARDS 29.11.2024 09:24 CET...

20.11.24 - 08:58	XFRA : 7C8: Aussetzung/Suspension (XETRA)
	DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT: THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT: INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTIL INVION LTD 7C8 AU000000IVX4 BAW/UFN...

20.11.24 - 07:52	XFRA : INSTRUMENT_SUSPENSION - AU000000IVX4 (XETRA)
	Instrument ID [1504] (7C8 - AU000000IVX4) suspended...

19.11.24 - 23:57	XFRA : CAPITAL ADJUSTMENT INFORMATION - 20.11.2024 - AU000000IVX4 (XETRA)
	Das Instrument 7C8 AU000000IVX4 INVION LTD EQUITY wird ex Kapitalmassnahme gehandelt am 20.11.2024 The instrument 7C8 AU000000IVX4 INVION LTD EQUITY is traded ex capital adjustment on 20.11.2024...

19.11.24 - 00:01	XFRA : CAPITAL ADJUSTMENT INFORMATION - 20.11.2024 - AU000000IVX4 (XETRA)
	Das Instrument 7C8 AU000000IVX4 INVION LTD EQUITY wird cum Kapitalmassnahme gehandelt am 19.11.2024 und ex Kapitalmassnahme am 20.11.2024 The instrument 7C8 AU000000IVX4 INVION LTD EQUITY is traded cum capital adjustment on 19.11.2024 and ex capital adjustment on 20.11.2024...

18.09.24 - 06:01

Invion′s INV043 candidate demonstrates positive results in Phase II prostate cancer trial (Small Caps)

Life sciences group Invion (ASX: IVX) has announced that its photodynamic technology (PDT) partner RMW Cho Group has completed a Phase II prostate cancer trial using its active pharmaceutical ingredient and lead cancer candidate INV043. The trial used six treatment cycles of INV043 as a monotherapy and a laser probe to apply red light to […] The post Invion's INV043 candidate demonstrates positive results in Phase II prostate cancer trial appeared first on Small Caps....

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Wer das Recht mit Füßen tritt, steht selten fest auf den Beinen. - Stanislaw Jerzy Lec

Partner: >Tradegate Börse | >Dukascopy | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram